Section Arrow
Quote
CUVL.NASDAQ
- Clinuvel Pharmaceuticals Limited
Quotes are at least 15-min delayed:2026/09/18 17:17 EDT
After Hours
Last
 5.9
0 (0.00%)
Bid
5.8
Ask
6
High 5.9 
Low 5.9 
Volume 1 
Regular Hours (Closed)
Last
 5.9
+0.04 (+0.68%)
Day High 
6.07 
Prev. Close
5.86 
1-M High
8.2 
Volume 
14.56K 
Bid
5.8
Ask
6
Day Low
5.9 
Open
5.91 
1-M Low
5.8 
Market Cap 
295.51M 
Currency 美元 
P/E 12.34 
%Yield 0.61 
10-SMA 6.01 
20-SMA 6.45 
50-SMA 6.76 
52-W High 8.92 
52-W Low 5.8 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.67/0.83
Enterprise Value
297.06M
Balance Sheet
Book Value Per Share
3.86
Cash Flow
Cash Flow Yield
0.09
Income Statement
Total Revenue
94.02M
Operating Revenue Per Share
1.03
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals3.83+0.29+8.19%-- 
After Hours 3.79 -0.04 -1.04%
TCRTAlaunos Therapeutics Inc.1.2-0.4-25.00%-- 
After Hours 1.3102 +0.1102 +9.18%
ROIVRoivant Sciences Ltd39.77-0.21-0.53%-- 
After Hours 39.2726 -0.4974 -1.25%
SLXNSilexion Therapeutics Corp.0.4355+0.0555+14.61%-- 
After Hours 0.4463 +0.0108 +2.48%
IOVAIovance Biotherapeutics10.25+0.23+2.30%-- 
After Hours 10.24 -0.01 -0.10%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Clinuvel Pharmaceuticals Ltd is a biopharmaceutical firm focused on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders. Its portfolio is centred around melanocortin peptides, with programs advancing in photomedicine and vitiligo. The company's main therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the U.S.A., Canada, Israel, and Australia as a systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Additionally, the firm is focused on developing and manufacturing Neuracthel to target neurological, endocrinological, and degenerative disorders. Geographically, it derives key revenue from Ireland.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.